Eli Lilly Korea Appoints Seiya Komatsu as New CEO
Eli Lilly Korea announced on July 1 that Seiya Komatsu has been appointed as the new CEO of Eli Lilly Korea.
Seiya Komatsu, the new CEO of Eli Lilly Korea, is a global business leader who joined Eli Lilly and Company (Lilly) headquarters as a recruiter and has since accumulated diverse experience in sales, marketing, business innovation, and organizational operations in both Japan and the United States.
After earning his MBA from Brigham Young University in the United States, Seiya Komatsu began his career in sales for the Diabetes Business Unit at Eli Lilly Japan. He later worked in business innovation at the global headquarters and served as branch manager for the Texas region in the U.S. Since 2020, he has overseen brand marketing for the incretin portfolio at Eli Lilly Japan, and immediately prior to his appointment as CEO of Eli Lilly Korea, he served as Executive Vice President and Head of the Neuroscience Business Unit at Eli Lilly Japan.
In his remarks upon taking office, Seiya Komatsu stated, "It is an honor to lead Eli Lilly Korea in this meaningful year, marking the 150th anniversary of Eli Lilly and Company. Korea is a core strategic market for Lilly, equipped with world-class bio-infrastructure and excellent research talent. I will do my utmost to ensure the rapid introduction of innovative new drugs and to improve treatment accessibility for patients in Korea." He added, "I will serve as a bridge connecting Lilly's global network with Korea's bio-pharmaceutical capabilities, carrying forward Lilly's 150-year legacy of patient-centered innovation and care here in Korea."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Eli Lilly Korea is currently contributing to the advancement of healthcare in Korea by supplying innovative treatments and conducting clinical research in various therapeutic areas, including cardiovascular and metabolic diseases, neurodegenerative diseases, oncology, and immunology. Recently, the company signed a USD 500 million investment agreement with the Ministry of Health and Welfare and is working to establish the Lilly Gateway Labs (LGL) hub in Songdo, Incheon, further strengthening its collaboration with Korea's bio-innovation ecosystem.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.